Michael Thurn
Chief Executive Officer at PHARMAUST LIMITED
Net worth: 335 184 $ as of 2024-05-30
Profile
Michael Thurn is currently the Chief Executive Officer, MD & Director at PharmAust Ltd.
He is also a Director at Marp Therapeutics Pty Ltd., Inmagene Biopharmaceuticals, and Impel Neuropharma.
Previously, he served as the Chief Executive Officer of Mimetica Pty Ltd.
from 2006 to 2014.
He also held the position of Chief Executive Officer at PharmAust Ltd.
from 2023 to 2024.
Additionally, he worked as the Chief Operating Officer & Executive Director at Botanix Pharmaceuticals Ltd.
from 2019 to 2020.
Dr. Thurn has a doctorate degree from the University of Technology Sydney, which he obtained in 1994.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PHARMAUST LIMITED
0.61% | 2024-05-30 | 2,400,000 ( 0.61% ) | 335 184 $ | 2024-05-30 |
Michael Thurn active positions
| Companies | Position | Start |
|---|---|---|
| PHARMAUST LIMITED | Chief Executive Officer | 2024-05-30 |
Marp Therapeutics Pty Ltd.
 Marp Therapeutics Pty Ltd. Medical/Nursing ServicesHealth Services Marp Therapeutics Pty Ltd. provides therapy services. The company is based in Melbourne, Australia. | Director/Board Member | - |
Former positions of Michael Thurn
| Companies | Position | End |
|---|---|---|
| PHARMAUST LIMITED | Chief Executive Officer | 2024-04-22 |
| BOTANIX PHARMACEUTICALS LIMITED | Chief Operating Officer | 2020-02-25 |
| ERASCA, INC. | Director/Board Member | - |
| Therapeutic Goods Administration | Corporate Officer/Principal | - |
| KAZIA THERAPEUTICS LIMITED | Corporate Officer/Principal | - |
Training of Michael Thurn
| University of Technology Sydney | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| KAZIA THERAPEUTICS LIMITED | Health Technology |
| BOTANIX PHARMACEUTICALS LIMITED | Health Technology |
| PHARMAUST LIMITED | Health Technology |
| ERASCA, INC. | Health Technology |
| Private companies | 6 |
|---|---|
YM BioSciences Australia Pty Ltd.
 YM BioSciences Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., YM BioSciences Australia Pty Ltd. develops cancer treatment pharmaceuticals. The company is based in Melbourne, Australia. | Health Technology |
Xenome Ltd.
 Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Health Technology |
Mimetica Pty Ltd.
 Mimetica Pty Ltd. Pharmaceuticals: MajorHealth Technology Mimetica Pty Ltd. is a holding company, which engages in the development of products for the treatment of acne. It has a drug discovery platform technology based on the rational design of small molecules that mimic natural peptide hormones. The company was founded in 2001 and is headquartered in Southbank, Australia. | Health Technology |
Spinifex Pharmaceuticals Pty Ltd.
 Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Health Technology |
| Therapeutic Goods Administration | |
Marp Therapeutics Pty Ltd.
Marp Therapeutics Pty Ltd. Medical/Nursing ServicesHealth Services Marp Therapeutics Pty Ltd. provides therapy services. The company is based in Melbourne, Australia. | Health Services |
- Stock Market
- Insiders
- Michael Thurn
